Tango Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-28.4%projected annual EPS growth
Analyst Coverage
12analysts covering
FY EPS (est.)
-$1.38next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Presentation of 2L/3L Pancreatic Cancer Combination Data at a Scientific Conference | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
Objective Response Rate (ORR) in Pancreatic Cancer (vopimetostat + daraxonrasib) Quarterly92.0%Target: Maintain high efficacy (>50-60% benchmark) in larger cohorts
6-Month Progression-Free Survival (PFS) Rate (vopimetostat + daraxonrasib) Quarterly90.0%Target: Establish durable PFS benefit in Phase 3 trials
Cash and Marketable Securities Balance Quarterly379.8MTarget: Sufficient to fund operations into 2028 (pre-offering baseline)
Watch Items
- Phase 3 Trial Initiation for Vopimetostat + DaraxonrasibTrigger: Regulatory feedback and protocol finalization in H2 2026Action: Monitor SEC filings and press releases for official trial start in 1L MTAP-deleted pancreatic cancer
- Vopimetostat Monotherapy Data in Lung CancerTrigger: Data disclosure expected in H2 2026Action: Evaluate clinical efficacy and safety profile compared to historical PRMT5 inhibitor benchmarks
- Initial TNG456 Glioblastoma Clinical DataTrigger: Data readout expected in H2 2026Action: Assess brain-penetrant PRMT5 inhibitor safety and early efficacy signals in GBM patients
Research as of 19 Jun 2026